Kochang

Researchers are evaluating the drug CMG190303 for treating adults with Type 2 Diabetes and Dyslipidemia. This Phase III trial aims to compare changes in blood sugar control (HbA1c) and cholesterol levels (LDL-C) between CMG190303 and standard treatments Rosuvastatin and Dapagliflozin. The study also focuses on assessing the safety of CMG190303 in this patient population. Participants receive different drug combinations over a 24-week period. One group takes CMG190303, which combines Dapagliflozin and Rosuvastatin with doses increasing every 8 weeks. Another group receives Dapagliflozin with a Rosuvastatin placebo, and a third group receives Rosuvastatin with a Dapagliflozin placebo, with doses also increasing every 8 weeks. This design allows comparison of the investigational drug against standard therapies. Throughout the study, participants undergo assessments including blood tests to monitor HbA1c and LDL-C levels. Researchers track changes from the start of the study to 24 weeks to evaluate treatment effects. Safety is monitored continuously, and medication adherence is checked during run-in periods. The study includes adults aged 19 to 80 years with Type 2 Diabetes and Dyslipidemia, and total participation lasts at least 24 weeks.

Researchers are conducting a large, multicenter registry study to observe the clinical outcomes of patients with unprotected left main coronary artery (LMCA) disease. The study aims to compare the results of medical treatment, coronary stenting with drug-eluting stents (DES), and coronary artery bypass grafting (CABG) in real-world daily practice. This research focuses on patients diagnosed with significant LMCA stenosis (over 50% narrowing) and collects data from centers across Korea and the Asia-Pacific region. Participants will receive treatment as determined by their medical team, which may include medication, PCI with DES, or CABG. Approximately 5,000 patients will be enrolled from about 65 centers. The study collects prospective data to evaluate and compare these treatment approaches without imposing specific interventions, reflecting routine clinical care. Participants will be followed over time with clinical assessments to monitor outcomes such as death, heart attacks, need for repeat vessel procedures, or stroke over a two-year period. The main outcome measured is a composite event rate including these serious cardiovascular events. Patients' medical history, clinical status, and follow-up data will be recorded to understand treatment effectiveness and patient prognosis in everyday practice.

Researchers are evaluating the use of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. This international, Phase 3, randomized, double-blind, placebo-controlled study aims to determine if dordaviprone treatment after standard frontline radiotherapy can extend overall survival and progression-free survival in this patient population. Participants must have histologically confirmed H3 K27M-mutant diffuse glioma and have completed frontline radiotherapy. Participants are assigned to receive either dordaviprone or a matching placebo. Those weighing 52.5 kg or more will receive 625 mg of dordaviprone (five 125-mg capsules) on dosing days, while those under 52.5 kg will receive a dose adjusted by body weight in 125-mg increments. The study compares the effects of dordaviprone treatment versus placebo after standard radiotherapy. The treatment dosing schedule and duration are based on the study protocol. During the study, participants will undergo brain MRI scans before and after radiotherapy, with imaging reviewed centrally. Researchers will monitor overall survival from randomization until death from any cause for up to approximately 44 months. Participants' performance status, corticosteroid and anti-seizure medication doses, and safety labs will be assessed. The study includes careful monitoring to evaluate the treatment's impact and safety over the follow-up period.